Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Naphthacenes: Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES.Mitoxantrone: An anthracenedione-derived antineoplastic agent.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Consolidation Chemotherapy: Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.P-Glycoprotein: A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Anthracyclines: Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Arabinonucleosides: Nucleosides containing arabinose as their sugar moiety.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Drug Resistance, Multiple: Simultaneous resistance to several structurally and functionally distinct drugs.Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.Asparaginase: A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 126.96.36.199.Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.Induction Chemotherapy: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.Drug Resistance: Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.Drug Agonism: Phenomena and pharmaceutics of compounds that selectively bind to a specific receptor and trigger a response. They mimic the action of endogenous biochemical molecules. Their effect can be countered by antagonists (DRUG ANTAGONISM).Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Acute Disease: Disease having a short and relatively severe course.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Cyclosporins: A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Trimethylsilyl Compounds: Organic silicon derivatives used to characterize hydroxysteroids, nucleosides, and related compounds. Trimethylsilyl esters of amino acids are used in peptide synthesis.6-Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.Leukemia, Myelomonocytic, Acute: A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Liposomes: Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.Carcinoma, Ehrlich Tumor: A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.Razoxane: An antimitotic agent with immunosuppressive properties.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.HL-60 Cells: A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Meningeal Carcinomatosis: Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Injections, Spinal: Introduction of therapeutic agents into the spinal region using a needle and syringe.Streptomyces: A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.Drug Screening Assays, Antitumor: Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.Leukemic Infiltration: A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Guanidines: A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Recurrence: The return of a sign, symptom, or disease after a remission.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Cytidine Monophosphate: Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Deoxycytidine Kinase: An enzyme that catalyzes reversibly the phosphorylation of deoxycytidine with the formation of a nucleoside diphosphate and deoxycytidine monophosphate. Cytosine arabinoside can also act as an acceptor. All natural nucleoside triphosphates, except deoxycytidine triphosphate, can act as donors. The enzyme is induced by some viruses, particularly the herpes simplex virus (HERPESVIRUS HOMINIS). EC 188.8.131.52.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Arabinonucleotides: Nucleotides containing arabinose as their sugar moiety.Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.Blast Crisis: An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.Multidrug Resistance-Associated Proteins: A sequence-related subfamily of ATP-BINDING CASSETTE TRANSPORTERS that actively transport organic substrates. Although considered organic anion transporters, a subset of proteins in this family have also been shown to convey drug resistance to neutral organic drugs. Their cellular function may have clinical significance for CHEMOTHERAPY in that they transport a variety of ANTINEOPLASTIC AGENTS. Overexpression of proteins in this class by NEOPLASMS is considered a possible mechanism in the development of multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although similar in function to P-GLYCOPROTEINS, the proteins in this class share little sequence homology to the p-glycoprotein family of proteins.Leukemia, Myeloid, Accelerated Phase: The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.Pyrazolones: Compounds with a five-membered heterocyclic ring with two nitrogens and a keto OXYGEN. Some are inhibitors of TNF-ALPHA production.Anthraquinones: Compounds based on ANTHRACENES which contain two KETONES in any position. Substitutions can be in any position except on the ketone groups.Central Nervous System Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Delayed-Action Preparations: Dosage forms of a drug that act over a period of time by controlled-release processes or technology.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Vidarabine: A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.K562 Cells: An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.Arabinofuranosylcytosine Triphosphate: A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Genes, MDR: Genes for MEMBRANE TRANSPORT PROTEINS that confer resistance to toxic compounds. Several superfamilies of these multidrug export proteins are known and found in both prokaryotes and eukaryotes.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Tablets: Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)Protein Denaturation: Disruption of the non-covalent bonds and/or disulfide bonds responsible for maintaining the three-dimensional shape and activity of the native protein.Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.Aminoglycosides: Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS.Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for P-glycoprotein and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of P-glycoprotein in both normal and malignant cells. (Leukemia 1997;11(7):1124-30)Drug Carriers: Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.Benzylisoquinolines: ISOQUINOLINES with a benzyl substituent.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Leukemia, Experimental: Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.Dexamethasone: An anti-inflammatory 9-fluoro-glucocorticoid.Gene Expression Regulation, Leukemic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Doxorubicin Idarubicin "daunorubicin hydrochloride". The American Society of Health-System Pharmacists. Archived from the ... Treatment is usually performed together with other chemotherapy drugs (such as cytarabine), and its administration depends on ... In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with ... Small volumes of daunorubicin can be wrapped up in these minuscule pods, which can then be released into a leukemia cell-filled ...
WHO Model List of Essential Medicines for Children
... α Bleomycinα Calcium folinateα Carboplatinα Cisplatinα Cyclophosphamideα Cytarabineα Dacarbazineα Dactinomycinα Daunorubicinα ... Other combinations that deliver the target doses required such as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can ... hydrochloride). Ergocalciferol can be used as an alternative. For use for rheumatic fever, juvenile arthritis, Kawasaki disease ...
WHO Model List of Essential Medicines
... α Carboplatinα Chlorambucilα Cisplatinα Cyclophosphamideα Cytarabineα Dacarbazineα Dactinomycinα Dasatinibα Daunorubicinα ... as hydrochloride) with 50 mg artesunate can be alternatives. For use only for the treatment of P. vivax infection For use only ... hydrochloride) Requires close medical supervision Ergocalciferol can be used as an alternative. For use for rheumatic fever, ...
Index of oncology articles
... iseganan hydrochloride - ISIS 2503 - ISIS 3521 - ISIS 5132 - islet cell - islet cell cancer - islet of Langerhans cell - ... daunorubicin - DCIS - de novo - death cap - debulking operation - decitabine - decortication - deferoxamine - defibrotide - ... cytarabine - cytochlor - cytogenetics - cytokine - cytology - cytomegalovirus - cytopenia - cytoplasm - cytotoxic - cytotoxic ... LY353381 hydrochloride - lycopene - lymph gland - lymph node - lymph node dissection - lymph node drainage - lymph node mapping ...
Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, ... Among the anthracyclines, doxorubicin and daunorubicin were the first, and were obtained from the bacterium Streptomyces ... The deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, ... daunorubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide and etoposide. Permanent thinning or hair loss can result ...
Pratélan Usada Pokok Modhèl WHO
WHO Model List of Essential Medicines
Or homatropine (hydrobromide) or cyclopentolate (hydrochloride) *^ For use in women actively breastfeeding at least 4 times per ... Cytarabineα. *Dacarbazineα. *Dactinomycinα. *Daunorubicinα. *Docetaxelα. *Doxorubicinα ... Other combinations that deliver the target doses required such as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can ...
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia - Full...
... daunorubicin hydrochloride, cytarabine) INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on ... Drug Information available for: Cytarabine Daunorubicin Daunorubicin hydrochloride Nilotinib Genetic and Rare Diseases ... I. To determine the complete response rates of combination nilotinib, cytarabine, and daunorubicin (daunorubicin hydrochloride ... Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia. This ...
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients...
Drug Information available for: Cytarabine Daunorubicin Daunorubicin hydrochloride Idarubicin hydrochloride Idarubicin ... Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients ... This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without ... INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV ...
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia - Full Text View -...
Drug: daunorubicin hydrochloride. Drug: dexamethasone. Drug: etoposide. Drug: leucovorin calcium. Drug: liposomal cytarabine. ... daunorubicin hydrochloride Drug: dexamethasone Drug: etoposide Drug: leucovorin calcium Drug: liposomal cytarabine Drug: ... Cytarabine. Vincristine. Daunorubicin. Asparaginase. 6-Mercaptopurine. Thiotepa. Levoleucovorin. Anti-Inflammatory Agents. ... NSC-34521 DNR Daunorubicin, NSC-82151 DTC101 Sustained release cytarabine G-CSF Granulocyte Colony-Stimulating Factor (Amgen), ...
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With...
... daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the gro ... vs standard daunorubicin hydrochloride and cytarabine.. Secondary. - To evaluate complete remission (CR) rates, duration of ... compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or. observation in treating older patients ... Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With ...
Irinotecan Injection Drug Shortage Notice - Drugs.com
Cyclophosphamide Injection Drug Shortage Notice - Drugs.com
Daunorubicin Hydrochloride Injection - Resolved. *Denileukin Diftitox Injection - No Longer Available - No Commercially ... Cytarabine Injection - Current. *Dacarbazine Injection - Resolved. *Dactinomycin Injection - Resolved. * ... Osmolex ER Osmolex ER (amantadine hydrochloride) is a proprietary formulation of immediate release and... ...
Vyxeos liposomal (previously known as Vyxeos) | European Medicines Agency
daunorubicin hydrochloride / cytarabine. International non-proprietary name (INN) or common name daunorubicin / cytarabine ... In this medicine, cytarabine and daunorubicin are contained in tiny fat droplets called liposomes. The liposomes are expected ... The active substances in Vyxeos, cytarabine and daunorubicin, have been used together to treat leukaemia and other types of ... The study compared Vyxeos with conventional cytarabine and daunorubicin infusions.. Patients given Vyxeos lived on average ...
US Patent # 9,566,348. Methods and compositions for the treatment of cancer and infectious disease using alpha(2)...
... cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate ... Amantadine Hydrochloride; Aranotin; Arildone; Atevirdine Mesylate; Avridine; Cidofovir; Cipamfylline; Cytarabine Hydrochloride ... Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Tilorone Hydrochloride; Trifluridine; Valacyclovir Hydrochloride; ... Clinafloxacin Hydrochloride; Clindamycin; Clindamycin Hydrochloride; Clindamycin Palmitate Hydrochloride; Clindamycin Phosphate ...
NCT02521493 Clinical Trial - National Cancer Institute
INDUCTION II: Patients receive cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV over 1-15 minutes, and ... INDUCTION III: Patients receive cytarabine, daunorubicin hydrochloride, and thioguanine as in Induction II. Induction III ... daunorubicin hydrochloride IV over 1-15 minutes, and thioguanine orally (PO) twice daily (BID) on days 1-4. Induction I ... INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 60-120 minutes on ...
Clinical Trials - Mayo Clinic Research
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients with ... Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients with ... Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways ... randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine ...
ANZCTR - Registration
Treatment: Drugs - cytarabine. Treatment: Drugs - daunorubicin hydrochloride. Treatment: Drugs - dexamethasone. Treatment: ... Treatment: Drugs: daunorubicin hydrochloride. Given IV, orally, intrathecally, intramuscularly, or subcutaneously. Treatment: ... 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or ... 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or ...
Search | Page 28 | Aplastic Anemia and MDS International Foundation
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage...
INDUCTION CHEMOTHERAPY: Patients receive cytarabine intrathecally (IT) on day 1; daunorubicin hydrochloride intravenously (IV) ... patients receive daunorubicin hydrochloride IV over 10-15 minutes on day 1, 8, 15, and 22; vincristine sulfate IV on days 1, 8 ... patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV over 1 hour on days 1-5, methotrexate IT on day ... cytarabine IV over 30 minutes or SC on days 30-33 and 37-40; mercaptopurine PO on days 29-42 and CD20 positive patients may ...
Clinical Trials - Mayo Clinic Research
Drugs used in chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the growth of ... This phase II trial studies how well daunorubicin hydrochloride, cytarabine, and nilotinib work in treating patients newly ... Giving daunorubicin hydrochloride with cytarabine and nilotinib may kill more cancer cells. ... A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed ...
Untreated Adult Acute Myeloid Leukemia Completed Phase 3 Trials for Daunorubicin (DB00694) - DrugBank
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients ... Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without ... Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid ... Untreated Adult Acute Myeloid Leukemia Completed Phase 3 Trials for Daunorubicin (DB00694). Back to Untreated Adult Acute ...
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell...
vincristine IV and daunorubicin hydrochloride IV on days 1, 8, 15, and 22; prednisone IV or. orally twice daily on days 1-28; ... on day 36; cytarabine IV or SC on days 36-39 and 43-46; and oral thioguanine on days 36-49.. NOTE: ** T-NHL patients with ... cytarabine IV or SC on days 29-32 and 36-39; and oral thioguanine on days 29-42. Patients. with DS also receive oral leucovorin ... 15, 22*, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV or. SC on days 8-11, 15-18, 50-53 and ...
Clinical Trial: NCT01085617 - My Cancer Genome
cytarabine. B1 - Standard therapy. daunorubicin hydrochloride. B1 - Standard therapy. etoposide. B1 - Standard therapy. ... Part 1 standard induction therapy (all patients*, weeks 1-4): Patients receive daunorubicin hydrochloride IV over 20 minutes ... Course 3 (delayed intensification): Patients receive daunorubicin hydrochloride IV over 20 minutes and vincristine sulfate IV ... Course 2: Patients receive cytarabine IV and high-dose etoposide IV over 30 minutes on days 1-5 and methotrexate IT on day 1. ...
Clinical Trial: NCT02828358 - My Cancer Genome
Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, ... Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, ... daunorubicin hydrochloride IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine IV or SC on days 2-5, 9-12, 16-19, and 23- ... daunorubicin hydrochloride intravenously (IV) over 1-15 minutes on days 8-9, cytarabine IV over 30 minutes on days 8-21 and IT ...
US Patent # 9,987,369. Vitamin functionalized gel-forming block copolymers for biomedical applications - Patents.com
Decitabine), Dactinomycin, Darbepoetin Alfa, Dasatinib, Daunomycin, Daunorubicin, Daunorubicin Hydrochloride, Daunorubicin ... Aminoglutethimide), Cytarabine, Cytarabine Liposomal, CYTOSAR-U.RTM. (Cytarabine), CYTOXAN.RTM. (Cyclophosphamide), Dacarbazine ... Nilutamide), Anastrozole, Arabinosylcytosine (Cytarabine), Ara-C(Cytarabine), ARANESP.RTM. (Darbepoetin Alfa), AREDIA.RTM. ( ... Bendamustine Hydrochloride), Tretinoin, TREXALL.RTM. (Methotrexate), TRISENOX.RTM. (Arsenic Trioxide), TSPA (Thiotepa), TYKERB. ...
VHB Life Sciences products
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in...
INDUCTION CHEMOTHERAPY: Patients receive cytarabine intrathecally (IT) on day 1; daunorubicin hydrochloride intravenously (IV) ... patients receive daunorubicin hydrochloride IV over 10-15 minutes on day 1, 8, 15, and 22; vincristine sulfate IV on days 1, 8 ... Beginning 8 weeks from day 1 of course 3, patients receive cytarabine, etoposide, and methotrexate as in course 1. Patients ... patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV over 1 hour on days 1-5, methotrexate IT on day ...
Liposome-Encapsulated Daunorubicin and Cytarabine for AML Subtypes - The ASCO Post
... combination of daunorubicin and cytarabine has different dosage recommendations than daunorubicin hydrochloride injection, ... Daunorubicin and cytarabine is a liposomal formulation of daunorubicin and cytarabine at a fixed 1:5 molar ratio. This ... combination of daunorubicin and cytarabine has a boxed warning against interchange with other daunorubicin- and/or cytarabine- ... cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. The drug name and dose must ...
DailyMed - DAUNORUBICIN HYDROCHLORIDE injection, solution
... and in combination with cytarabine, has produced complete remission rates of 53 to 65%. ... daunorubicin 20 MG per 4 ML Injection. SY. 4. 309650. daunorubicin (as daunorubicin hydrochloride 5.34 MG) 20 MG per 4 ML ... DAUNORUBICIN HYDROCHLORIDE (UNII: UD984I04LZ) (DAUNORUBICIN - UNII:ZS7284E0ZP) DAUNORUBICIN. 5 mg in 1 mL. ... Each mL contains daunorubicin hydrochloride, USP equivalent to 5 mg of daunorubicin, 9 mg sodium chloride, hydrochloric acid ( ...
Search results for SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[ConditionSearch] Anemia - ICH GCP - Clinical Trials...
Intervention: Asparaginase, Cytarabine, Daunorubicin Hydrochloride, Methotrexate, Therapeutic Hydrocortisone, Thioguanine June ... Intervention: Cytarabine, Etoposide, Idarubicin, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell ... Intervention: Filgrastim, Vitamin E, Busulfan, Cytarabine, Etoposide, Fludarabine Phosphate, Isotretinoin, Topotecan ... Intervention: Anti-thymocyte Globulin, Filgrastim, Busulfan, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide ...
Patent US8017749 - Compositions and methods to treat cancer with cupredoxins and CpG rich DNA - Google Patents
... cytarabine, fluorouracil, doxorubicin hydrochloride, daunorubicin, idarubicin, bleomycin sulfate, mitomycin C, actinomycin D, ... cytarabine, fluorouracil, doxorubicin hydrochloride, daunorubicin, idarubicin, bleomycin sulfate, mitomycin C, actinomycin D, ... irinotecan hydrochloride, betamethosone, gemcitabine hydrochloride, altretamine, and topoteca and any analogs or derivatives ... irinotecan hydrochloride, betamethosone, gemcitabine hydrochloride, altretamine, and topoteca and any analogs or derivatives ...
Search results for SEARCH[STUDY] TILT[STUDY:STUDY-FIRST-POSTED] ALL - ICH GCP - Clinical Trials Registry
Intervention: Oblimersen Sodium, Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study ... Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia. Conditions: Adult Acute ... Intervention: Filgrastim, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Leucovorin Calcium, ... Intervention: Filgrastim, Rituximab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, ...
Clinical Trials Using Imatinib Mesylate - National Cancer Institute
... such as daunorubicin hydrochloride, cyclophosphamide, vincristine sulfate, prednisone, leucovorin calcium, cytarabine, ... This partially randomized phase II trial studies how well intensive combination chemotherapy and liposomal cytarabine (a form ... Intensive Combination Chemotherapy and Liposomal Cytarabine in Treating Patients with Acute Lymphoblastic Leukemia or ... Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride with Asparaginase in Treating ...
Bruno C Medeiros, MD | Stanford Medicine Profiles
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients ... This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without ... Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways ... induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin ...
CyclophosphamideEtoposideCerubidineHigh Dose CytarabineLiposomeDecitabineVyxeosClofarabineSodiumPatients receive cytarabine IVEpirubicin HydrochlorideAntineoplasticRemissionAntimitotic and cytotoxic activityDoseTreat neuroblastomaHypersensitivity reactionsFludarabineLiposomal formulationAcuteVialVYXEOSPatientsDays
- All children had been treated with dexamethasone for 4 days followed by remission induction with prednisone acetate, vincristine, daunorubicin hydrochloride and pegaspargase on days 5 to 28, and cyclophosphamide, cytarabine and mercaptopurine on days 29 to 35. (healio.com)
- This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). (utswmed.org)
- Giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide may kill more cancer cells. (bioportfolio.com)
- PURPOSE: This phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous stem cell transplant. (bioportfolio.com)
- To evaluate the 1-year survival of patients with relapsed multiple myeloma treated with bortezomib, pegylated liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide. (bioportfolio.com)
- Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. (bioportfolio.com)
- INTENSIFICATION I: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 60-120 minutes on days 1-3. (cancer.gov)
- INTENSIFICATION II: Patients receive cytarabine and etoposide as in Intensification I. Intensification II continues for a minimum of 28 days. (cancer.gov)
- INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 60-120 minutes on days 1-5. (cancer.gov)
- CONSOLIDATION THERAPY: Beginning after the second course of blinatumomab (patients randomized to the blinatumomab group) or after intensification therapy (patients not randomized to blinatumomab), patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV over 1 hour on days 1-5, methotrexate IT on day 1, and pegaspargase IM or IV on day 5, and CD20 positive patients may optionally receive rituximab IV on day 5. (centerwatch.com)
High Dose Cytarabine4
- INDUCTION II: Patients receive high dose cytarabine IV over 1-3 hours every 12 (Q12) hours on days 1-4 and mitoxantrone hydrochloride IV over 15-30 minutes on days 3-6. (cancer.gov)
- INTENSIFICATION II: Patients receive high dose cytarabine IV over 3 hours Q12 hours on days 1, 2, 8, and 9. (cancer.gov)
- I. To compare event-free survival (EFS) between patients with acute myeloid leukemia (AML) who receive standard 7+3 (cytarabine and daunorubicin hydrochloride) or idarubicin and high-dose cytarabine (IA) to patients who receive IA + vorinostat. (uchicagomedicine.org)
- ARM II: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. (uchicagomedicine.org)
- On August 3, 2017, a liposome-encapsulated combination of daunorubicin and cytarabine (Vyxeos) was approved for treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. (ascopost.com)
- Approval was based on improved overall survival with the liposome-encapsulated combination of daunorubicin and cytarabine in an open-label phase III study in which 309 patients aged 60 to 75 years were randomized to receive the liposome-encapsulated combination (n = 153) or a standard (7+3) daunorubicin/cytarabine combination (n = 156). (ascopost.com)
- The liposome-encapsulated combination of daunorubicin and cytarabine carries warnings/precautions for serious/fatal hemorrhagic events with associated prolonged thrombocytopenia, cardiotoxicity, severe/life-threatening hypersensitivity reactions, local tissue necrosis at the site of drug extravasation, and embryofetal toxicity. (ascopost.com)
- The dose for the first cycle of induction is daunorubicin at 44 mg/m 2 and cytarabine at 100 mg/m 2 liposome via 90-minute infusion on days 1, 3, and 5. (ascopost.com)
- VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). (vyxeospro.com)
- VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. (vyxeospro.com)
- Daunorubicine is out there as daunorubicin hydrochloride and daunorubicin citrate liposome. (medicalterms.info)
- 21 . The liposome of claim 20 , wherein the antineoplastic agent is Doxorubicin hydrochloride. (google.it)
- The active substances in Vyxeos are daunorubicin and cytarabine. (europa.eu)
- The active substances in Vyxeos, cytarabine and daunorubicin, have been used together to treat leukaemia and other types of cancer for many years. (europa.eu)
- The study compared Vyxeos with conventional cytarabine and daunorubicin infusions. (europa.eu)
- Patients given Vyxeos lived on average around 9.6 months after treatment, whereas those given conventional cytarabine and daunorubicin lived about 6 months. (europa.eu)
- Vyxeos improved survival compared with conventional cytarabine and daunorubicin in patients with acute myeloid leukaemia who have a poor prognosis and few alternatives. (europa.eu)
- VYXEOS has different dosage recommendations than other daunorubicin and cytarabine-containing products. (vyxeospro.com)
- Do not use in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin or any other components of VYXEOS. (vyxeospro.com)
- Based on the pharmacokinetic Phase 1 trial data, the median half-lives of daunorubicin and cytarabine are prolonged with VYXEOS versus free drug. (vyxeospro.com)
- For VYXEOS, the estimated half-life of daunorubicin and cytarabine were 32 hours and 40 hours, respectively, when administered in VYXEOS. (vyxeospro.com)
- VYXEOS is contraindicated in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin, or any component of the formulation. (vyxeospro.com)
- VYXEOS contains daunorubicin, which has a known risk of cardiotoxicity. (vyxeospro.com)
- To compare the overall survival of older patients with newly diagnosed acute myeloid leukemia (AML) treated with clofarabine as induction therapy and consolidation therapy vs standard daunorubicin hydrochloride and cytarabine. (clinicaltrialsgps.com)
- Giving epratuzumab together with cytarabine and clofarabine may kill more cancer cells. (stanford.edu)
- PURPOSE: This phase II trial is studying the side effects and how well giving epratuzumab together with cytarabine and clofarabine works in treating patients with relapsed or refractory acute lymphoblastic leukemia. (stanford.edu)
Patients receive cytarabine IV1
- Daunorubicin hydrochloride is extensively metabolized in the liver and other tissues, mainly by cytoplasmic aldo-keto reductases, producing daunorubicinol, the major metabolite which has antineoplastic activity. (nih.gov)
- 6 . The process of claim 5 , wherein the antineoplastic agent is Doxorubicin hydrochloride. (google.it)
- Determine the response rate of intrathecal sustained release cytarabine (DTC101) in patients with first bone marrow remission with first isolated CNS relapse. (clinicaltrials.gov)
- OBJECTIVES: - Determine, preliminarily, the safety of incorporating arsenic trioxide (ATO) into cytarabine and daunorubicin hydrochloride-based consolidation therapy followed by tretinoin maintenance therapy in patients receiving induction tretinoin and daunorubicin hydrochloride with acute promyelocytic leukemia (APL) induced into remission with tretinoin and daunorubicin hydrochloride. (ichgcp.net)
Antimitotic and cytotoxic activity2
- Daunorubicin has antimitotic and cytotoxic activity achieved by forming complexes with DNA, thus inhibiting topoisomerase II activity, inhibiting DNA polymerase activity, affecting the regulation of gene expression, and producing DNA-damaging free radicals. (ascopost.com)
- Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. (nih.gov)
- Approximately 40% of the drug in the plasma is present as daunorubicinol within 30 minutes and 60% in 4 hours after a dose of daunorubicin. (nih.gov)
- ARM I: Patients receive standard dose cytarabine intravenously (IV) continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. (uchicagomedicine.org)
- This phase II trial studies how well daunorubicin hydrochloride, cytarabine, and nilotinib work in treating patients newly diagnosed with acute myeloid leukemia. (clinicaltrials.gov)
- This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. (clinicaltrials.gov)
- Patients under 60years of age with acute nonlymphocytic leukemia is suggested a dosage of 45mg/m2 per day of Daunorubicine IV infusion and given on the first 3days of the first course of treatment. (medicalterms.info)
- VYXEOS has different dosage recommendations than other daunorubicin and cytarabine-containing products. (vyxeospro.com)
- Do not use in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin or any other components of VYXEOS. (vyxeospro.com)
- Welcome to the presentation titled "VYXEOS® (daunorubicin and cytarabine) Clinical Data. (vyxeospro.com)
- Sevelamer Hydrochloride is used for High Blood Phosphorus Levels In Patients With Severe Kidney Disease and other conditions. (medzeellifescience.com)
- Sevelamer Hydrochloride is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms.High Blood Phosphorus Levels In Patients With Severe Kidney Disease. (medzeellifescience.com)
- And then it was compared to 7 days of cytarabine and 3 days of daunorubicin, our conventional 7+3. (vyxeospro.com)
- And then, on the alternate arm, it was 5 days of cytarabine and 2 days of daunorubicin. (vyxeospro.com)
- and for consolidation in the other arm it was 5 days of cytarabine and 2 days of daunorubicin. (vyxeospro.com)